Abstract

When activated through toll-like receptors (TLRs), macrophages generate IL-33, an IL-1 family member that induces innate immune responses through ST2 signaling. LPS, a TLR4 ligand, induces macrophages to generate prostaglandin E2 (PGE2) through inducible COX-2 and microsomal PGE2 synthase 1 (mPGES-1) (1). We demonstrate that IL-33 production by bone marrow-derived murine macrophages (bmMFs) requires the generation of endogenous PGE2 and the intrinsic expression of EP2 receptors to amplify NF-κB-dependent, LPS-induced IL-33 expression via exchange protein activated by cAMP (EPAC). Compared with WT cells, bmMFs lacking either mPGES-1 or EP2 receptors displayed reduced LPS-induced IL-33 levels. A selective EP2 agonist and, to a lesser extent, EP4 receptor agonist potentiated LPS-induced IL-33 generation from both mPGES-1-null and WT bmMFs, whereas EP1 and EP3 receptor agonists were inactive. The effects of PGE2 depended on cAMP, were mimicked by an EPAC-selective agonist, and were attenuated by EPAC-selective antagonism and knockdown. LPS-induced p38 MAPK and NF-κB activations were necessary for both IL-33 production and PGE2 generation, and exogenous PGE2 partly reversed the suppression of IL-33 production caused by p38 MAPK and NF-κB inhibition. Mice lacking mPGES-1 showed lower IL-33 levels and attenuated lung inflammation in response to repetitive Alternaria inhalation challenges. Cumulatively, our data demonstrate that endogenous PGE2, EP2 receptors, and EPAC are prerequisites for maximal LPS-induced IL-33 expression and that exogenous PGE2 can amplify IL-33 production via EP2 and EP4 receptors. The ubiquitous induction of mPGES-1-dependent PGE2 may be crucial for innate immune system activation during various IL-33 driven pathologic disorders.

Highlights

  • IL-33 is a recently discovered member of the IL-1 cytokine family that binds to toll-like receptors (TLRs)/IL1R2 superfamily receptor ST2

  • Exogenous prostaglandin E2 (PGE2) can potentiate IL-33 expression by dendritic bone marrow-derived murine macrophage; EPAC, exchange protein activated by cAMP; WB, Western blotting; qPCR, quantitative PCR; CREB, cAMP-response element-binding protein; ILC2, group 2 innate lymphoid cell; recombinant murine MCSF (rmMCSF), recombinant murine macrophage colony-stimulating factor; 6-bnz-cAMP, N6-benzoyladenosine-3Ј, 5Ј-cyclic monophosphate; 8-pCPT2-O-Me-cAMP AM, 8-(4-chlorophenylthio)-2Ј-O-methyladenosine-3Ј, 5Ј-cyclic monophosphate; FPA 124, dichloro[(2Z)-2-[(4-oxo-4H-1-benzopyran-3-yl)methylene]hydrazinecarbothioamide; 10-DEBC, 10-[4Ј-(N,N-Diethylamino)butyl]-2-chlorophenoxazine hydrochloride; APC, allophycocyanin

  • Stimulation with LPS dose-dependently induced the release of PGE2 by WT cells, which was significantly reduced in cells lacking microsomal PGE2 synthase 1 (mPGES-1) (Fig. 1A)

Read more

Summary

Results

To determine the role of endogenous PGE2 in LPS-mediated IL-33 production, we stimulated bmMFs with LPS at concentrations of 0.5 and 1.0 ␮g/ml. Stimulation of WT and mPGES-1 KO bmMFs with the EP2 receptor-selective agonist AE1-259-01 (1.0 ␮M) in combination with LPS significantly enhanced IL-33 production but failed to do so in EP2 KO cells (Fig. 1E). To determine whether cAMP was involved in potentiation of IL-33 production, we stimulated bmMFs with LPS in the absence or presence of the pharmacologic adenyl cyclase activator forskolin (50.0 ␮M) or a cell-permeable cAMP analog, 8-bromo-cAMP (100.0 ␮M). Both agents significantly potentiated LPS-induced IL-33 expression in mPGES-1 KO and EP2 KO cells and potentiated the response of WT cells (Fig. 3A). ILC2 expansion, and IL-33 expression were identified in EP2 receptor knock-out mice (n ϭ 1 experiment, data not shown)

Discussion
Experimental procedures
Bone marrow macrophages
ELISA and Western blotting
Intranasal inhalation challenge and flow cytometry
Statistical analysis
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call